Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.

Pharmacogenetics and genomics - 1 Feb 2010

Nordestgaard Børge G, Kontula Kimmo, Benn Marianne, Dahlöf Björn, de Faire Ulf, Edelman Jonathan M, Eliasson Erik, Fyhrquist Frej, Hille Darcy A, Ibsen Hans, Lyle Paulette A, Berg Kåre, Sandberg Mia, Sethi Amar A, Wong Peggy H, Os Ingrid

Abstract excerpt

OBJECTIVE: This pharmacogenetics substudy from the Losartan Intervention for Endpoint reduction in Hypertension study in patients with hypertension and left ventricular hypertrophy (LVH) treated with the angiotensin receptor blocker losartan versus the beta-blocker atenolol for 4.8 years tested w...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Blood Pressure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endpoint Determination

Share to Heart Rate

Share to Hypertrophy, Left Ventricular

Share to INDEL Mutation

Share to Losartan

Share to Peptidyl-Dipeptidase A

Source

Identifiers

PMID: 20065889
DOI: 10.1097/FPC.0b013e328333f70b

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20065889-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.PMID 20065889Read ↗

Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.Semantic proximity Read ↗

Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.Semantic proximity Read ↗

ACE insertion deletion polymorphisms and effectiveness of statin therapy.Semantic proximity Read ↗

Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic SubjectsSemantic proximity Read ↗

Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II.Semantic proximity Read ↗

ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?Semantic proximity Read ↗

Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction.Semantic proximity Read ↗

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.Semantic proximity Read ↗

Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.Semantic proximity Read ↗

ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With NephropathySemantic proximity Read ↗

Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.Semantic proximity Read ↗

Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.